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Background: Epidemiological studies showed that higher plasma urate was associated with lower risk for Parkinson’s
disease (PD) and slower disease progression. Recent genome-wide association studies (GWAS) consistently showed
that several single nucleotide polymorphisms (SNPs) in the solute carrier family 2 member 9 gene (SLC2A9 ) were
associated with plasma urate concentration and the risk of gout.
Methods: We conducted a case–control study to examine twelve tag SNPs of the SLC2A9 gene in relation to PD
among 788 cases and 911 controls of European ancestry. Odds ratios (OR) and 95% confidence intervals (CI) were
derived from logistic regression models, adjusting for age, sex, smoking and caffeine consumption.
Results: These SNPs were all in linkage disequilibrium (R2 > 0.7). None of them were associated with PD risk. Among
women, however, there was a suggestion that the presence of the minor allele of one SNP (rs7442295)
was related to a small increase in PD risk [OR (95% CI) = 1.48 (1.01-2.16)].
Conclusion: This study provides little support for genetic variations of SLC2A9 and PD risk.Parkinson’s disease (PD) is the second most prevalent
neurodegenerative disease and the causes are largely un-
known. It has been long hypothesized that, during PD
development, oxidative stress contributes to the loss of
dopaminergic neurons in the substantia nigra. Uric acid
is a potent endogenous antioxidant that effectively
scavenges reactive nitrogen and oxygen radicals, and
thus may protect against PD. Data from large observa-
tional studies consistently showed that higher plasma
urate predicted a lower risk of PD [1,2] and slower dis-
ease progression [3]. The nature of this association is
however debatable as one may argue that the association
is due to reverse causation that lower plasma urate
is secondary to the underlying PD pathogenesis.
Investigations into urate genetics may help clarify this
observation. For example, by examining the association
of urate related genetic alleles with PD, we may have an
unbiased assessment of urate in relation to PD risk to
the extent that these genetic alleles affect plasma urate, a
concept called “Mendelian randomization” [4]. Recent
genome-wide association studies (GWAS) consistently* Correspondence: chenh2@niehs.nih.gov
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reproduction in any medium, provided the orshowed that the minor alleles of several single nucleotide
polymorphisms (SNPs) in the solute carrier family 2
member 9 gene (SLC2A9 ) were associated with lower
plasma urate concentration and predicted lower gout risk
[5,6]. We therefore examined these genetic variations in
relation to PD risk in a case–control study of 788 PD cases
and 911 controls, all non-Hispanic Caucasians.Methods
Details of the study method were published previously
[7]. Briefly, we first identified self-reported PD cases
from a large population-based cohort – the NIH-AARP
Diet and Health Study. We then asked the treating
physicians to fill out a short diagnostic questionnaire
and to send a copy of relevant medical records. The
diagnoses were either confirmed by their treating
neurologists or via medical record review by a move-
ment disorder specialist (XH). Only confirmed PD
patients were included in the present analyses. Controls
were randomly selected from participants of the same
cohort who did not report a PD diagnosis and they were
frequency matched to cases by sex, ethnicity, and year of
birth. Therefore, both cases and controls were from
the same base population and no additional exclusion
criteria were applied. Both cases and controls provided. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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SNPs were selected from SLC2A9 based on recent
GWAS findings on plasma urate [5,6]. Genotyping was
conducted using the Illumina BeadXpress platform with
a call rate of 99.9%. All participants provided written
consent and the study protocol was approved by relevant
institutional review boards. To avoid population stratifi-
cation, the current analysis was limited to 788 cases and
911 controls who self-reported as non-Hispanic Whites.
Hardy-Weinberg equilibrium among controls was
confirmed with chi-square statistics for all SNPs (P > 0.05).
Odds ratios (ORs) and 95% confidence intervals (CIs) were
derived from logistic regression models under the assump-
tion of logit-additive allelic effects, adjusting for age, sex,
smoking status and caffeine intake. All statistical analyses
were performed using SAS version 9.2 (SAS Institute Inc,
Cary, NC), and two sided p < 0.05 was considered
statistically significant. We performed power calculations
with Quanto version 1.2.4.
Results
Table 1 showed population characteristics of PD patients
and controls. Cases and controls were matched by birth
year in five year groups and gender. For cases, the aver-
age age of PD diagnosis was 66.6 ± 7.4 years and the
average age of PD onset was 65.7 ± 7.4 years. As
expected, cases were less likely to smoke and had lower
caffeine intake than controls.
The 12 SNPs from SLC2A9 were all in linkage disequi-
librium (R2 > 0.7). In general, none of these SNPs were
associated with PD in overall and gender specific ana-
lyses (Table 2). Among women, there was a suggestion
that the presence of the minor allele of one SLC2A9
SNP (rs7442295) was related to a small increase in PD
risk (OR = 1.48, 95%CI = 1.01-2.16). The direction of this
relation is consistent with that would be predicted basedTable 1 Population characteristics of cases and controls*
Control (%) Case (%)
N 911 788
Gender
Men 725 (79.58) 606 (76.90)
Women 186 (20.42) 182 (23.10)
Age at baseline, years 63.5 ± 4.8 63.0 ± 5.0
Smoking status
Never 318 (34.91) 363 (46.07)
Former 540 (59.28) 391 (49.62)
Current 49 (5.38) 23 (2.92)
Caffeine intake, mg/day 364.91 ± 362.26 295.54 ± 334.69
Age at onset, year 65.73 ± 7.43
Age at diagnosis, year 66.65 ± 7.37
* Numbers may not add up to total due to missing.on the relationship of this SNP to plasma urate. The as-
sociation was however not statistical significant after
adjusting for multiple comparisons.
Discussion
PD has an insidious onset and a long latency period,
therefore epidemiological findings are often subject to
competing explanations of biology versus reverse causal-
ity that the exposures are secondary to the underlying
disease process. Although the exact biological mech-
anisms are yet to be revealed, higher plasma urate has
been linked to lower PD risk in several prospective stud-
ies [1,2]. Plasma urate increases with age in human and
has been hypothesized to protect dopaminergic neurons
via its potent antioxidant properties. On the other hand,
one cannot exclude the possibility that plasma urate
rises in response to increased free radicals as a result of
PD pathogenesis.
Genetic analyses may help to clarify such epidemiologic
findings. Unlikely diet, lifestyle or many other environ-
mental exposures, genetic variants are fixed and not
affected by disease process. They are randomly assorted
during gamete formation in a process that is similar to
randomization in clinical trials. “Mendelian randomization”
has thus been proposed to investigate causality of
epidemiologic findings by circumventing reverse causation
and confounding [4]. If a non-genetic exposure is causally
related to an outcome, robust genetic determinants of this
exposure are expected to relate to the outcome. Previous
Mendelian randomization analyses using large samples sup-
port a causative relationship of plasma urate with gout, but
argue against one with cardiovascular diseases [8,9].
To the best of our knowledge, this is the first study to
follow up recent GWAS finding on SLC2A9 and plasma
urate for PD research, and some of these SNPs were
included in the above-mentioned studies on gout and
cardiovascular diseases [8,9]. SLC2A9 was the first urate
transporter gene that was identified from GWAS and
has shown the most robust association with plasma
urate and gout in previous studies [8,9]. Reduced renal
excretion of urate is the most important cause of high
plasma urate and gout, and SLC2A9 encodes a
major urate transporter [10]. Although the exact causal
variants of the SLC2A9 gene that determine plasma
urate are yet to be identified, GWAS studies have linked
several tag SNPs in this gene to the level of plasma
urate. However, in GWAS, these SNPs only explain a
small amount of plasma urate concentration [5] and
thus the expected OR for PD associated with these SNPs
are smaller than 1.1 for both men and women. Although
our study is among the largest population-based studies
on PD with both genetic and environmental data, the
power of our study to detect such weak associations was
limited. With 788 cases and 911 controls, we estimated
Table 2 Selected SLC2A9 SNPs in relation to the risk of Parkinson’s disease*
All Men Women
SNPs MAF OR (95% CI) P MAF OR (95% CI) P MAF OR (95% CI) P
Case Control Case Control Case Control
rs16890979 0.23 0.22 1.06 (0.90-1.24) 0.51 0.22 0.23 0.99 (0.82-1.19) 0.92 0.23 0.18 1.40 (0.96-2.03) 0.08
rs13129697 0.26 0.27 0.99 (0.85-1.16) 0.91 0.26 0.27 0.95 (0.79-1.13) 0.53 0.28 0.24 1.19 (0.84-1.69) 0.33
rs737267 0.25 0.25 1.01 (0.86-1.18) 0.91 0.25 0.25 0.97 (0.81-1.16) 0.70 0.25 0.22 1.20 (0.85-1.70) 0.30
rs6855911 0.25 0.25 1.00 (0.85-1.18) 0.98 0.24 0.25 0.95 (0.80-1.14) 0.61 0.25 0.22 1.21 (0.85-1.71) 0.29
rs4697700 0.24 0.23 1.03 (0.88-1.22) 0.69 0.24 0.24 1.02 (0.85-1.22) 0.87 0.23 0.21 1.13 (0.79-1.62) 0.49
rs4481233 0.19 0.19 1.01 (0.85-1.21) 0.90 0.19 0.20 0.96 (0.79-1.18) 0.72 0.19 0.16 1.25 (0.84-1.87) 0.28
rs7442295 0.22 0.21 1.06 (0.90-1.26) 0.50 0.22 0.22 0.98 (0.81-1.19) 0.83 0.23 0.17 1.48 (1.01-2.16) 0.04
rs6449213 0.19 0.19 1.01 (0.85-1.21) 0.88 0.20 0.20 0.97 (0.79-1.18) 0.74 0.19 0.16 1.23 (0.83-1.84) 0.31
rs1014290 0.25 0.25 1.04 (0.88-1.22) 0.67 0.26 0.25 1.07 (0.89-1.28) 0.48 0.23 0.24 0.91 (0.63-1.31) 0.62
rs12509955 0.21 0.22 0.99 (0.84-1.18) 0.93 0.22 0.22 1.00 (0.82-1.20) 0.96 0.19 0.20 0.99 (0.67-1.46) 0.95
rs17251963 0.21 0.20 1.05 (0.88-1.25) 0.59 0.21 0.20 1.02 (0.84-1.24) 0.83 0.20 0.18 1.17 (0.78-1.75) 0.44
rs12510549 0.21 0.22 0.96 (0.81-1.14) 0.65 0.21 0.23 0.91 (0.76-1.10) 0.34 0.20 0.18 1.22 (0.83-1.79) 0.31
* Odds ratios and 95% confidence intervals were derived from logistic regression models under the assumption of logit-additive allelic effects, adjusting for age, sex, smoking status and caffeine intake.
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1.25 or lower than 0.79 for a minor allele frequency of
25%. Other limitations of the current study include the
lack of plasma urate, and that we did not include genetic
variations from other key genes that are related to
plasma urate as identified in later GWAS studies [11].
In summary, our analysis did not support a relation-
ship between these SLC2A9 SNPs and PD in men, but it
does not exclude a modest association for women.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JG contributed to study concept, conducted data analysis, and drafted the
manuscript. HX and XH contributed to data collection and provided critical
comments. HC contributed to data collection, study concept, and
manuscript preparation and oversaw this project. All authors read and




This study was supported by the intramural research program of the NIH,
the National Institute of Environmental Health Sciences (Z01-ES-101986), and
NIH extramural grant to Dr. Huang (NS06722).
Author details
1Epidemiology Branch, National Institute of Environmental Health Sciences,
Research Triangle Park, North Carolina, USA. 2Molecular Genetics Core Facility,
National Institute of Environmental Health Sciences, Research Triangle Park,
North Carolina, USA. 3Department of Neurology, Pennsylvania State
University-Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
Received: 16 November 2012 Accepted: 17 February 2013
Published: 19 February 2013
References
1. Weisskopf M, O'Reilly E, Chen H, Schwarzschild M, Ascherio A: Plasma Urate
and Risk of Parkinson's Disease. Am J Epidemiol 2007, 166(5):561–567.
2. Chen H, Mosley TH, Alonso A, Huang X: Plasma Urate and Parkinson's
Disease in the Atherosclerosis Risk in Communities (ARIC) Study.
Am J Epidemiol 2009, 169(9):1064–1069.
3. Ascherio A, LeWitt PA, Xu K, et al: Urate as a Predictor of the Rate of
Clinical Decline in Parkinson Disease. Arch Neurol 2009, 66(12):1460–1468.
4. Lawlor DA, Harbord RM, Sterne JAC, Timpson N, Smith GD: Mendelian
randomization: Using genes as instruments for making causal inferences
in epidemiology. Stat Med 2007, 27(8):1133–1163.
5. Doring A, Gieger C, Mehta D, et al: SLC2A9 influences uric acid
concentrations with pronounced sex-specific effects. Nat Genet 2008,
40(4):430–436.
6. Vitart V, Rudan I, Hayward C, et al: SLC2A9 is a newly identified urate
transporter influencing serum urate concentration, urate excretion and
gout. Nat Genet 2008, 40(4):437–442.
7. Gao J, Xu H, Weinberg C, et al: An exploratory study on the CHRNA3-
CHRNA5-CHRNB4 cluster, smoking, and Parkinson's disease. Neurodegener
Dis 2011, 8(5):296–299.
8. Dehghan A, Köttgen A, Yang Q, et al: Association of three genetic loci
with uric acid concentration and risk of gout: a genome-wide
association study. Lancet 2008, 372(9654):1953–1961.
9. Yang Q, Kottgen A, Dehghan A, et al: Multiple genetic loci influence
serum urate levels and their relationship with gout and cardiovascular
disease risk factors. Circ Cardiovasc Genet 2010, 3(6):523–530.10. Caulfield MJ, Munroe PB, O'Neill D, et al: SLC2A9 is a high-capacity urate
transporter in humans. PLoS Med 2008, 5(10):e197.
11. Anzai N, Jutabha P, Amonpatumrat-Takahashi S, Sakurai H: Recent advances
in renal urate transport: characterization of candidate transporters
indicated by genome-wide association studies. Clin Exp Nephrol 2012,
16(1):89–95.
doi:10.1186/2047-9158-2-5
Cite this article as: Gao et al.: Short communication: genetic variations
of SLC2A9 in relation to Parkinson’s disease. Translational
Neurodegeneration 2013 2:5.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
